韩国初治患者中整合酶抑制剂耐药突变的前瞻性观察研究。
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Treatment-naïve Patients in Korea: a Prospective, Observational Study.
机构信息
Center for Infectious Diseases Research, Department of Internal Medicine, National Medical Center, Seoul, Korea.
出版信息
J Korean Med Sci. 2018 May 14;33(25):e173. doi: 10.3346/jkms.2018.33.e173. eCollection 2018 Jun 18.
Abstract
The present study investigated prevalence of integrase strand transfer inhibitors (INSTI) resistance mutations in HIV-1-infected antiretroviral therapy (ART)-naïve patients in Korea. From 106 plasma samples, amplification and sequencing of integrase genes was performed, and major or minor mutations were calculated by the Stanford HIV drug resistance mutation interpretation algorithm. No major INSTI resistance mutations were found, and 14 minor mutations were detected in 13 (12.3%) patients. The present data support the recommendation that routine testing for INSTI resistance mutations before starting ART is not necessary.
摘要
本研究调查了韩国未经抗逆转录病毒治疗 (ART) 的 HIV-1 感染患者中整合酶链转移抑制剂 (INSTI) 耐药突变的流行情况。从 106 份血浆样本中，对整合酶基因进行了扩增和测序，并通过斯坦福 HIV 耐药突变解释算法计算了主要或次要突变。未发现主要的 INSTI 耐药突变，在 13 名 (12.3%)患者中检测到 14 种次要突变。本数据支持在开始 ART 之前常规检测 INSTI 耐药突变并非必要的建议。
相似文献
1
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Treatment-naïve Patients in Korea: a Prospective, Observational Study.韩国初治患者中整合酶抑制剂耐药突变的前瞻性观察研究。
J Korean Med Sci. 2018 May 14;33(25):e173. doi: 10.3346/jkms.2018.33.e173. eCollection 2018 Jun 18.
2
Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea.韩国初治和经治HIV患者中抗逆转录病毒治疗整合酶链转移抑制剂耐药突变情况
AIDS Res Hum Retroviruses. 2019 Feb;35(2):213-216. doi: 10.1089/AID.2018.0213. Epub 2018 Oct 23.
3
Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.印度西部初治和经治抗逆转录病毒治疗个体中整合酶链转移抑制剂相关耐药性的缺失
AIDS Res Hum Retroviruses. 2019 Jun;35(6):567-571. doi: 10.1089/AID.2018.0272. Epub 2019 Apr 8.
4
Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience.初治和经治的HIV-1感染患者中整合酶链转移抑制剂耐药突变的流行情况：单中心经验
AIDS Res Hum Retroviruses. 2018 Jul;34(7):570-574. doi: 10.1089/AID.2018.0006. Epub 2018 May 9.
5
Prevalence of integrase strand transfer inhibitor (INSTIs) resistance mutations in Henan Province, China (2018-2020).中国河南省整合酶抑制剂耐药突变体的流行情况（2018-2020 年）。
Infection. 2021 Dec;49(6):1195-1202. doi: 10.1007/s15010-021-01668-9. Epub 2021 Jul 19.
6
Short Communication: Trends in Transmitted Drug Resistance in Treatment-Naive HIV Patients in Korea.简短通讯：韩国初治HIV患者中传播耐药性的趋势
AIDS Res Hum Retroviruses. 2020 Nov;36(11):905-909. doi: 10.1089/AID.2020.0054. Epub 2020 Sep 7.
7
Prevalence and analysis of acquired and transmitted integrase strand transfer inhibitor-associated HIV-1 drug resistance in Chongqing, China.中国重庆获得性和传播性整合酶抑制剂相关的 HIV-1 耐药性的流行情况及分析。
Virulence. 2023 Dec;14(1):2278254. doi: 10.1080/21505594.2023.2278254. Epub 2023 Nov 9.
8
Primary resistance to integrase strand-transfer inhibitors in Europe.欧洲对整合酶链转移抑制剂的原发性耐药性。
J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.
9
Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance.HIV-1整合酶的自然多态性S119R增强了对第一代整合酶链转移抑制剂的耐药性。
Antiviral Res. 2015 Jul;119:84-8. doi: 10.1016/j.antiviral.2015.04.014. Epub 2015 May 5.
10
Primary resistance against integrase strand transfer inhibitors in integrase strand transfer inhibitor-naive patients failing first- and second-line ART in Tanzania.坦桑尼亚一线和二线抗逆转录病毒治疗失败的整合酶抑制剂初治患者中对整合酶抑制剂的原发耐药。
J Antimicrob Chemother. 2022 Oct 28;77(11):3138-3143. doi: 10.1093/jac/dkac295.
引用本文的文献
1
Variability in HIV-1 Integrase Gene and 3'-Polypurine Tract Sequences in Cameroon Clinical Isolates, and Implications for Integrase Inhibitors Efficacy.喀麦隆临床分离株中 HIV-1 整合酶基因和 3'-多聚嘧啶区序列的变异性及其对整合酶抑制剂疗效的影响。
Int J Mol Sci. 2020 Feb 25;21(5):1553. doi: 10.3390/ijms21051553.
本文引用的文献
1
Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.北卡罗来纳州 2010-2016 年预处理整合酶抑制剂耐药情况。
AIDS. 2017 Oct 23;31(16):2235-2244. doi: 10.1097/QAD.0000000000001611.
2
Prevalence of integrase inhibitor resistance mutations in Austrian patients recently diagnosed with HIV from 2008 to 2013.2008年至2013年近期诊断出感染艾滋病毒的奥地利患者中整合酶抑制剂耐药性突变的流行情况。
Infection. 2017 Apr;45(2):165-170. doi: 10.1007/s15010-016-0936-5. Epub 2016 Aug 16.
3
Polymorphic substitution E157Q in HIV-1 integrase increases R263K-mediated dolutegravir resistance and decreases DNA binding activity.HIV-1整合酶中的多态性替代E157Q增加了R263K介导的多替拉韦耐药性并降低了DNA结合活性。
J Antimicrob Chemother. 2016 Aug;71(8):2083-8. doi: 10.1093/jac/dkw109. Epub 2016 Apr 15.
4
Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.多替拉韦功能单药疗法对整合酶链转移抑制剂耐药患者的HIV-1病毒学应答的影响。
Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11.
5
Primary resistance to integrase strand-transfer inhibitors in Europe.欧洲对整合酶链转移抑制剂的原发性耐药性。
J Antimicrob Chemother. 2015 Oct;70(10):2885-8. doi: 10.1093/jac/dkv202. Epub 2015 Jul 17.
6
Lack of resistance to integrase inhibitors among antiretroviral-naive subjects with primary HIV-1 infection, 2007-2013.2007 - 2013年原发性HIV - 1感染的初治抗逆转录病毒治疗受试者中对整合酶抑制剂缺乏耐药性
Antivir Ther. 2015;20(1):77-80. doi: 10.3851/IMP2780. Epub 2014 May 15.
7
Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012.2009-2012 年美国临床标本中 HIV 整合酶链转移抑制剂耐药情况。
Clin Infect Dis. 2014 Feb;58(3):423-31. doi: 10.1093/cid/cit697. Epub 2013 Oct 21.
8
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.在 BENCHMRK 研究中，raltegravir 治疗 HIV 长达 5 年的疗效和安全性：两项随机、安慰剂对照试验的最终结果。
Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7.
9
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK.在初治 HIV-1 感染患者中，与依非韦伦相比，联合替诺福韦/恩曲他滨时，拉替拉韦具有持久的疗效和安全性：STARTMRK 的最终 5 年结果。
J Acquir Immune Defic Syndr. 2013 May 1;63(1):77-85. doi: 10.1097/QAI.0b013e31828ace69.
10
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.初治人类免疫缺陷病毒 1 型感染者接受拉替拉韦或依非韦伦联合替诺福韦/恩曲他滨治疗：STARTMRK 的 156 周结果。
Clin Infect Dis. 2011 Oct;53(8):807-16. doi: 10.1093/cid/cir510.
Zotero 插件